Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RGS12 | O14924 | 4/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 3/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | AGER | Q15109 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349637 | 1.00 | RGS12 (0.42) | RGS12APOBEC3AAPOBEC3GMEN1TP53 | |
| SCHEMBL16727678 | 0.93 | RGS12 (0.43) | RGS12APOBEC3AAPOBEC3GMEN1TP53 | |
| SCHEMBL17920915 | 0.93 | RGS12 (0.42) | RGS12APOBEC3AAPOBEC3GMEN1TP53 | |
| SCHEMBL28667047 | 0.92 | RGS12 (0.44) | RGS12APOBEC3AAPOBEC3GMEN1TP53 | |
| SCHEMBL28667045 | 0.92 | RGS12 (0.44) | RGS12APOBEC3AAPOBEC3GMEN1TP53 | |
| SCHEMBL23750628 | 0.87 | RGS12 (0.41) | RGS12APOBEC3AAPOBEC3GMEN1KMT2A | |
| SCHEMBL14998079 | 0.82 | GRM5 (0.33) | POLB | |
| SCHEMBL14930066 | 0.82 | KDM4E (0.39) | USP2CASR | |
| SCHEMBL20958044 | 0.79 | RGS12 (0.41) | RGS12APOBEC3AAPOBEC3GMEN1TP53 | |
| SCHEMBL20958045 | 0.79 | RGS12 (0.41) | RGS12APOBEC3AAPOBEC3GMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230331712-A1 | SOLID FORMS OF (R)-1(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-19 | — | — | US | disclosed |
| EP-4253381-A2 | SOLID FORMS OF (R)-1-(2,2-DIFLUOROBENZO[D][1,3]D IOXOL-5-YL)-N-(1-(2,3-DIHYDROXYP ROPYL)-6-FLUORO-2-(1-HYDROXY- 2-METHYLPROPAN-2-YL)-1H-INDOL- 5-YL) CYCLOPROPANECARBOXAMIDE | Vertex Pharmaceuticals Incorporated (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3925607-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-3925607-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2023-06-28 | — | — | EP | disclosed |
| US-11578062-B2 | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-14 | — | — | US | disclosed |
| CN-110840847-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-113912617-A | Substituted tricycles and methods of use | 艾伯维公司 | 2022-01-11 | — | — | CN | disclosed |
| US-8563593-B2 | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130158071-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130143919-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130131107-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2560651-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2560650-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120015999-A1 | FORMULATIONS OF (R)-1-(2,2-DIFLUOROBENZO[D] [1,3] DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2011133953-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133956-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110257223-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257223-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, CLCN2, ABCB11 | RGS12 138/4885APOBEC3A 4825/4885APOBEC3G 4782/4885 |
| US-20230331712-A1 | SOLID FORMS OF (R)-1(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR1A, HTR1D | RGS12 3236/4885APOBEC3A 2347/4885APOBEC3G 2940/4885 |
| US-20120015999-A1 | FORMULATIONS OF (R)-1-(2,2-DIFLUOROBENZO[D] [1,3] DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE | HTR1A, HTR1D, HTR1B | RGS12 2696/4885APOBEC3A 1130/4885APOBEC3G 1230/4885 |
| US-20130158071-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | CFTR, ABCB11, ABCC5 | RGS12 1943/4885APOBEC3A 4382/4885APOBEC3G 4025/4885 |
| US-11578062-B2 | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR1A, HTR1D | RGS12 3236/4885APOBEC3A 2347/4885APOBEC3G 2940/4885 |
| US-20130131107-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | CFTR, ABCB11, SLC26A4 | RGS12 2136/4885APOBEC3A 4280/4885APOBEC3G 3773/4885 |
| US-20130143919-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | CFTR, ABCB11, ABCC5 | RGS12 1943/4885APOBEC3A 4382/4885APOBEC3G 4025/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | RGS12 135/4885APOBEC3A 4787/4885APOBEC3G 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.